Executive summary: US Patent 7,713,947 claims a specific oral cladribine treatment regimen for multiple sclerosis defined by (a) an induction period with a total induction dose of ~1.7 to 3.5 mg/kg, (b) a cladribine-free interval of ~8 to 10 months, (c) a maintenance period with a lower total maintenance dose, and (d) a further cladribine-free interval. The claims are method-of-treatment claims with multiple tiers of specificity (dose, calendar durations, dosing frequency, optional repetition of maintenance cycles, and optional combination with interferon-beta). The estate scope is concentrated on this “pulsed/short-cycle, long cladribine-free” oral MS schedule, not on cladribine chemistry, not on generic formulation composition, and not on broader MS use-cases outside these timing and dose relationships.

H1: Scope and claims analysis of US Patent 7,713,947 (oral cladribine regimen for multiple sclerosis)

What exactly does US 7,713,947 claim: regimen timing, dose bands, and repeat structure?

Core claim architecture (repeated across independent claims):
A method of treating multiple sclerosis by oral administration of a cladribine-containing formulation, in a sequence of:

Induction period (i)
- Total cladribine dose at end of induction: ~1.7 mg/kg to ~3.5 mg/kg
- Duration:
  - Explicit dependent claim bands include up to ~4 months (claim 2) with exemplars at ~2, ~3, ~4 months (claims 3–5), and up to ~3 months (claim 6).
  - Broader independent claim (claims 20/36) sets induction at ~2 to ~4 months.
Cladribine-free period (ii)
- Length: ~8 to ~10 months
- Dependent claim shows examples: ~10 months (claims 9, 25, 41, 42).
Maintenance period (iii)
- Oral dosing during maintenance
- Relationship constraint: total maintenance dose is lower than induction total
- Specific dosing targets are pinned in dependents to ~1.7 mg/kg (claims 11, 13, 36 baseline, 28/29/27/43).
Second cladribine-free period (iv)
- No cladribine administered
- Dependent exemplars include ~10 months (claims 9, 26, 41, 42, 28).

Repeat cycle capability:

One independent claim includes repeating steps (iii) to (iv) one, two, or three times (claim 12).
Other dependents cover at least one or two times (claims 17, 33, 47) or “at least two times” (claim 34).
This is significant because it defines a multi-cycle pulsing framework around a fixed cladribine-free interval concept.

How narrow are the claim limits: is the regimen only “cladribine + oral” or is the schedule the real novelty?

The claims are regimen-timing and dose-relationship constrained, with multiple independent claim sets built around the same treatment skeleton. Key narrowing features are:

Total dose bands tied to body weight (mg/kg):
- Induction total dose must land in ~1.7 to ~3.5 mg/kg.
- Maintenance total dose is explicitly lower than induction total.
- Specific numeric maintenance target appears as ~1.7 mg/kg in multiple claim chains (claims 11, 13, 20/28/29/36/43).
Calendar-free windows are strict by claim wording:
- ~8 to ~10 months cladribine-free after induction.
- A cladribine-free period (iv) is included and exemplified at ~10 months in dependents.
Induction duration is not unconstrained:
- Explicit dependent examples (2, 3, 4 months; up to 3 or up to 4 months).
- Independent claim 20/36 uses ~2 to ~4 months.
Maintenance duration bounds:
- Independent claim 20 sets maintenance at ~2 to ~4 months.
- Dependents include ~2 months (claim 10, 27, 28, 43).
Optional dosing frequency bands:
- During induction, oral dosing occurs 1 to 7 days per month (claim 16).
  This is an additional schedule limiter that can matter in product labeling differences between alleged infringement and non-infringement.

Bottom line: the claim scope is driven less by drug identity (cladribine is known) and more by the specific oral pulsed dosing cadence and dose sequencing.

What are the independent claim groupings and how do they differ (claims 1, 20, 36)?

Claim 1 (independent; less numeric “range framing” in the independent text you provided)

Sets induction total dose range (~1.7–~3.5 mg/kg)
Sets cladribine-free period (ii) range (~8–~10 months)
Requires maintenance total dose lower than induction total
Includes cladribine-free period (iv) (duration not explicitly ranged in the snippet, but examples exist in dependents like ~10 months)
Adds downstream dependents on induction duration, specific dose endpoints, daily dose ranges, dosing days per month, repeat count, and interferon-beta combination.

Claim 20 (independent; explicitly uses ranges for all time blocks)

Induction period: ~2 to ~4 months
Induction total: ~1.7 to ~3.5 mg/kg
Cladribine-free period (ii): ~8 to ~10 months
Maintenance: ~2 to ~4 months
Maintenance total dose lower than induction total
Cladribine-free period (iv): included without further range text in your excerpt

Claim 36 (independent; pins maintenance total to ~1.7 mg/kg)

Uses the same induction and cladribine-free windows as claim 20
Maintenance total dose is about 1.7 mg/kg (more restrictive than the “lower than induction” requirement alone)
Cladribine-free (iv) included

Practical consequence for infringement mapping: claim 36’s maintenance target of ~1.7 mg/kg creates a sharper dividing line than claim 20, which only requires maintenance be lower than induction.

What dosage and administration details are claimed: daily dose and induction dosing days per month?

Daily dose range

Claimed daily cladribine dose: 3 to 30 mg (claim 14)
Example daily dose: 10 mg (claim 15; also claim 31)

Induction dosing frequency

Induction period dosing is 1 to 7 days per month (claim 16)

These elements matter because many cladribine oral regimens in the marketplace or in study protocols differ by daily unit dose, number of dosing days, and tapering practices. The claims you provided constrain these parameters within the pulse concept.

Does US 7,713,947 cover combination therapy with interferon-beta?

Yes. Multiple dependent claims include:

Combination with interferon-beta (claims 18, 19, 35, 48)

Scope impact:
This expands coverage to regimens where cladribine oral pulsing is used alongside interferon-beta, while still anchored to the same sequencing and dose/time structure.

How do the “repeated maintenance cycle” claims expand or limit infringement risk?

Key provisions:

Steps (iii) to (iv) are repeated one, two, or three times (claim 12)
Or repeated at least one or two times (claims 17, 33, 47)
Or at least two times (claim 34)

What this changes:
If an accused regimen uses only a single maintenance block, it may fall short of repeat-cycle dependents. If an accused regimen uses multiple maintenance-and-cladribine-free cycles, it can more readily map to the repeat dependent claim chains, increasing infringement exposure.

What patent estate scope is implied beyond the independent claims: method-only coverage vs formulation or process coverage?

Based solely on the claims text you provided, US 7,713,947 is a method-of-treatment claim set. The claim language:

Centers on oral administration of a “formulation comprising cladribine”
Defines treatment sequence, dose totals, and timing intervals
Does not, in the excerpt, recite:
- the cladribine composition/chemical structure
- tablet/capsule excipient composition
- specific manufacturing/process parameters
- dissolution/PK formulation specifications

Business inference for licensing or freedom-to-operate positioning:
This patent primarily blocks regimen implementation that fits the dose and scheduling constraints, even if the formulation product is different, generic, or bioequivalent, so long as the claimed “sequence” is executed.

How strong is US 7,713,947 as a blocking patent: claim breadth and “design-around” handles

Strength factors (broad handles for enforcement)

Wide induction total dose range: ~1.7 to ~3.5 mg/kg
Wide cladribine-free window: ~8 to ~10 months
Wide induction and maintenance duration ranges (in claim 20): induction ~2 to ~4 months; maintenance ~2 to ~4 months
Repeat cycles are captured in dependents across one to multiple repeats

Design-around handles (where accused regimens can avoid)

The main non-infringement levers are:

Induction total dose outside ~1.7–~3.5 mg/kg
Cladribine-free interval (ii) outside ~8–~10 months
Maintenance total dose that is not lower than induction (for claim 1/20) or not ~1.7 mg/kg (for claim 36)
Maintenance-and-cladribine-free cycles used fewer times than the claimed repeat dependents
Dosing pattern outside 1 to 7 days per month during induction
Avoiding interferon-beta co-administration (if dependents are asserted)

How does the claim language map to cladribine oral MS treatment protocols (regimen features that matter in practice)?

US 7,713,947’s claimed regimen has four practical signature features for mapping to real-world MS protocols:

Oral cladribine pulsing in an “induction” window of up to ~4 months (or ~2–4 months)
Long cladribine-free interval of ~8–10 months after induction
Lower-dose maintenance block with total maintenance dose < induction total, with a specific maintenance example at ~1.7 mg/kg
Second cladribine-free interval with exemplars around 10 months and the ability to repeat maintenance cycles

This combination creates a highly specific “administration choreography,” which is where method claims tend to be most enforceable.

What would an accused product need to do to infringe: “sequence compliance” checklist

To infringe independent regimen claims, the accused regimen must satisfy all the sequential constraints in the relevant independent claim set:

Oral cladribine administered to treat MS
Induction total within ~1.7–~3.5 mg/kg
Induction period duration within the relevant range (claim 20: ~2–4 months; claim 1 has dependents specifying examples)
No cladribine for ~8–10 months after induction
Maintenance period administered such that total maintenance is:
- lower than induction total (claims 1 and 20)
- and for claim 36, about 1.7 mg/kg
No cladribine during cladribine-free (iv), with dependents exemplifying ~10 months
If asserted under dependents: induction dosing 1–7 days/month, daily dose 3–30 mg, repeat cycles (iii)-(iv) at least once/twice or up to three times, and/or combination with interferon-beta

What patent litigation or Orange Book status issues arise from a method claim like this?

A method-of-treatment patent can be asserted even when the product is approved under different labeling, but the factual trigger for infringement is the actual regimen being used. For generic entry risk assessments:

Orange Book listing typically identifies patents listed for approval (often for composition/formulation or method-of-use).
A method claim like this is most relevant when a generic or biosimilar-like product’s labeling and prescribing instructions are aligned with the claimed regimen.
If labeling carve-outs or physician-available deviations exist, exposure can shift to off-label use or to specific dosing schedules that are marketed.

(Your prompt requests litigation/regulatory status, but you did not provide Orange Book listings, FDA approval dates, or any litigation docket details tied to US 7,713,947. No additional status can be asserted from the claim text alone.)

How many distinct claim “themes” are there in US 7,713,947 and what coverage do they represent?

From the provided claim set, coverage themes can be grouped as follows:

Claim theme	What is claimed	Key ranges/examples in provided claims
Core regimen sequence	Induction → cladribine-free → maintenance → cladribine-free	Induction total: ~1.7–3.5 mg/kg; cladribine-free (ii): ~8–10 months; maintenance total < induction; cladribine-free (iv) included
Induction duration sub-scope	Induction lasts up to or about fixed months	Up to ~4 months; ~2, ~3, ~4 months; up to ~3 months
Maintenance dosing sub-scope	Maintenance total lower than induction; sometimes fixed to ~1.7 mg/kg	Claim 36: maintenance total about 1.7 mg/kg; multiple claim dependents align
Cycle repeat	Repeat maintenance and cladribine-free blocks	Steps (iii)-(iv) repeated one/two/three times; at least one/two times
Daily dose sub-scope	Daily cladribine amount	3–30 mg; example 10 mg
Induction dosing frequency	Number of dosing days in induction month	1–7 days/month
Combination therapy sub-scope	Concomitant interferon-beta	Claims include combination with interferon-beta

Coverage implication: the estate is not a single “simple” claim. It is a layered regimen-control patent with multiple dependent hooks that can be asserted based on which dosing features are present in the accused schedule.

What is the likely “claim-to-design-around” sensitivity for developers of generic cladribine oral regimens?

From a design-around standpoint, the highest-sensitivity variables are:

Total induction dose (mg/kg)
Length of the post-induction cladribine-free interval (ii)
Maintenance total dose relationship (and specifically the ~1.7 mg/kg constraint in claim 36)
Maintenance cycle count and whether dependents (iii)-(iv) repeated are met
Induction dosing days per month (claim 16)

Generic development may not change pharmacology or formulation, but regimen changes in prescribing instructions or clinical protocols can shift infringement risk materially for method claims.

Key Takeaways

US 7,713,947 is a method-of-treating multiple sclerosis patent centered on an oral cladribine regimen with a defined induction total dose (~1.7–~3.5 mg/kg) followed by a long cladribine-free interval (~8–~10 months), then a lower-dose maintenance period, then another cladribine-free interval, with optional repeat maintenance cycles.
The most enforceable claim features are the dose total constraints (mg/kg) and calendar-free windows, not cladribine chemistry.
Dependent claims add enforceability hooks around induction duration, daily dose (3–30 mg; 10 mg example), 1–7 dosing days per month, maintenance cycle repetition, and interferon-beta combination.
Practical infringement mapping is a sequence compliance exercise: the accused regimen must match the induction total dose band, the cladribine-free timing, and the maintenance dose relationship (and specifically the ~1.7 mg/kg maintenance total where claim 36 is implicated).

FAQs

1) Do US 7,713,947 claims require a specific cladribine-free interval length after maintenance (period iv)?

Claim language includes “a cladribine-free period wherein no cladribine is administered” after maintenance, with multiple dependents exemplifying the ~10-month duration (e.g., claims 9, 26, 28, 41, 42). The precise period iv length is therefore most explicitly pinned in dependents.

2) Can a regimen avoid infringement by changing only the daily mg dose while keeping mg/kg totals?

The claims include both total dose in mg/kg and in dependents a daily dose range (3–30 mg; 10 mg example). If mg/kg totals are kept within the claimed bands but daily dose falls outside the dependents, infringement exposure depends on which claim is asserted.

3) Does the patent cover regimens that use cladribine continuously without “cladribine-free” gaps?

No. The method claims require cladribine-free periods after induction and after maintenance, with no cladribine administered during those intervals.

4) Are interferon-beta combination regimens covered even if the cladribine schedule matches the claimed pulse pattern?

Yes. Dependent claims explicitly include combination with interferon-beta (claims 18, 19, 35, 48) while retaining the claimed oral cladribine regimen structure.

5) If a treatment protocol uses only one maintenance block, is that outside the scope?

Some dependents require that steps (iii) to (iv) are repeated at least once/twice (claims 12, 17, 33–34, 47). Whether that avoids infringement depends on whether an independent claim alone is asserted or a dependent repeat-structured claim is asserted.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	04106909	Dec 22, 2004

PCT Information
PCT Filed	December 20, 2005	PCT Application Number:	PCT/EP2005/056954
PCT Publication Date:	June 29, 2006	PCT Publication Number:	WO2006/067141

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1827461	⤷ Start Trial	122018000021	Germany	⤷ Start Trial
European Patent Office	1827461	⤷ Start Trial	300930	Netherlands	⤷ Start Trial
European Patent Office	1827461	⤷ Start Trial	CR 2018 00010	Denmark	⤷ Start Trial
European Patent Office	1827461	⤷ Start Trial	2018C/010	Belgium	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,713,947

Summary for Patent: 7,713,947